Epidemiologic data in adult men exhibit a strong relationship between erectile dysfunction (ED) and lower urinary tract symptoms suggestive of benign prostatic hyperplasia (LUTS/BPH), indicating that men affected by ED should also be investigated for LUTS/BPH and those presenting with storage or voiding LUTS should be investigated for co-morbid ED. Common pathophysiolgical mechanisms underlying both LUTS/BPH and ED, including alteration of NO/cGMP or RhoA/Rho-kinase signaling and/or vascular or neurogenic dysfunction, are potential targets for proposed phosphodiesterase type 5 inhibitors (PDE5-Is). Several randomized controlled trials and only a few reviews including all commercially available PDE5-Is demonstrated the safety and efficacy of these drugs in the improvement of erectile function and urinary symptoms, in patients affected either by ED, LUTS, or both conditions.

PDE5-Is for the Treatment of Concomitant ED and LUTS/BPH / Gacci, M; Sebastianelli, Arcangelo; Salvi, Matteo; Vignozzi, Linda; Corona, G; Mcvary, Kt; Kaplan, Sa; Oelke, M; Maggi, Mario; Carini, Marco. - In: CURRENT BLADDER DYSFUNCTION REPORTS. - ISSN 1931-7212. - STAMPA. - 8:(2013), pp. 150-159. [10.1007/s11884-013-0184-9]

PDE5-Is for the Treatment of Concomitant ED and LUTS/BPH

Gacci, M;SEBASTIANELLI, ARCANGELO;SALVI, MATTEO;VIGNOZZI, LINDA;MAGGI, MARIO;CARINI, MARCO
2013

Abstract

Epidemiologic data in adult men exhibit a strong relationship between erectile dysfunction (ED) and lower urinary tract symptoms suggestive of benign prostatic hyperplasia (LUTS/BPH), indicating that men affected by ED should also be investigated for LUTS/BPH and those presenting with storage or voiding LUTS should be investigated for co-morbid ED. Common pathophysiolgical mechanisms underlying both LUTS/BPH and ED, including alteration of NO/cGMP or RhoA/Rho-kinase signaling and/or vascular or neurogenic dysfunction, are potential targets for proposed phosphodiesterase type 5 inhibitors (PDE5-Is). Several randomized controlled trials and only a few reviews including all commercially available PDE5-Is demonstrated the safety and efficacy of these drugs in the improvement of erectile function and urinary symptoms, in patients affected either by ED, LUTS, or both conditions.
2013
8
150
159
Gacci, M; Sebastianelli, Arcangelo; Salvi, Matteo; Vignozzi, Linda; Corona, G; Mcvary, Kt; Kaplan, Sa; Oelke, M; Maggi, Mario; Carini, Marco
File in questo prodotto:
File Dimensione Formato  
Gacci et al., PDE5.pdf

Accesso chiuso

Tipologia: Pdf editoriale (Version of record)
Licenza: Tutti i diritti riservati
Dimensione 238.79 kB
Formato Adobe PDF
238.79 kB Adobe PDF   Richiedi una copia

I documenti in FLORE sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificatore per citare o creare un link a questa risorsa: https://hdl.handle.net/2158/821533
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 16
  • ???jsp.display-item.citation.isi??? ND
social impact